Cargando…

Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial

Calcineurin inhibitors (CNIs, eg, tacrolimus) reduce short‐term kidney transplant failure, but chronic nephrotoxicity may contribute to late transplant loss. Elective conversion to inhibitors of the mammalian target of rapamycin (mTOR, eg, sirolimus) pathway might avoid long‐term CNI renal damage an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haynes, Richard, Blackwell, Lisa, Staplin, Natalie, Herrington, William G., Emberson, Jonathan, Judge, Parminder K., Storey, Benjamin C., Landray, Martin J., Harden, Paul N., Baigent, Colin, Friend, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001618/ https://www.ncbi.nlm.nih.gov/pubmed/29226570 http://dx.doi.org/10.1111/ajt.14619

Ejemplares similares

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol
por: Haynes, Richard, et al.
Publicado: (2013)

Evidence for the Prevention and Treatment of Stroke in Dialysis Patients
por: Herrington, William, et al.
Publicado: (2015)

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank
por: Zhu, Pengfei, et al.
Publicado: (2020)

Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease
por: Herrington, William, et al.
Publicado: (2017)

Neprilysin inhibition in chronic kidney disease
por: Judge, Parminder, et al.
Publicado: (2015)

Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology
por: Staplin, Natalie, et al.
Publicado: (2022)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
por: Storey, Benjamin C., et al.
Publicado: (2018)

Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD
por: Morton, Rachael L., et al.
Publicado: (2016)

Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
por: Storey, Benjamin C., et al.
Publicado: (2018)

Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP)
por: Haynes, Richard, et al.
Publicado: (2014)

Impact of Outcome Adjudication in Kidney Disease Trials: Observations From the Study of Heart and Renal Protection
por: Herrington, William G., et al.
Publicado: (2023)

Allocated but not treated: the silent 16% – Authors' reply
por: Horby, Peter, et al.
Publicado: (2022)

Impact of CKD on Household Income
por: Morton, Rachael L., et al.
Publicado: (2017)

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
por: Staplin, Natalie, et al.
Publicado: (2021)

Chronic kidney disease, heart failure and neprilysin inhibition
por: Haynes, Richard, et al.
Publicado: (2020)

Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)
por: Staplin, Natalie, et al.
Publicado: (2016)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection
por: Reith, C., et al.
Publicado: (2017)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
por: Herrington, William G, et al.
Publicado: (2018)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
por: Herrington, William G, et al.
Publicado: (2019)

Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection
por: Mafham, Marion M, et al.
Publicado: (2018)

Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease
por: Schlackow, Iryna, et al.
Publicado: (2019)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
por: Schlackow, Iryna, et al.
Publicado: (2017)

Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply
por: Horby, Peter, et al.
Publicado: (2021)

What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?
por: Kent, Seamus, et al.
Publicado: (2015)

Estimated Glomerular Filtration Rate and the Risk of Major Vascular Events and All-Cause Mortality: A Meta-Analysis
por: Mafham, Marion, et al.
Publicado: (2011)

The evolving role of alemtuzumab (Campath-1H) in renal transplantation
por: Pham, Phuong-Thu T, et al.
Publicado: (2009)

Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP)
por: Mihaylova, Borislava, et al.
Publicado: (2016)

Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis
por: Dalakas, Marinos C., et al.
Publicado: (2009)

Calcineurin Inhibitors in Membranous Nephropathy
por: Ponticelli, Claudio, et al.
Publicado: (2021)

Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial–Adjudicated Direct Follow-up Data in the UK: Secondary Analysis of the ASCEND Randomized Clinical Trial
por: Harper, Charlie, et al.
Publicado: (2021)

Reliability of major bleeding events in UK routine data versus clinical trial adjudicated follow-up data
por: Harper, Charlie, et al.
Publicado: (2023)

Accelerometer-measured physical activity and functional behaviours among people on dialysis
por: Nawab, Khizr A, et al.
Publicado: (2020)

Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomization study
por: Donovan, Killian, et al.
Publicado: (2023)

The risk of early and late cytomegalovirus DNAemia associated with Campath use in stem cell transplant recipients
por: Buyck, Hubertus C, et al.
Publicado: (2009)

Role of Klotho in Chronic Calcineurin Inhibitor Nephropathy
por: Luo, Kang, et al.
Publicado: (2019)

The Effects of CAMPATH-1H on Cell Viability Do Not Correlate to the CD52 Density on the Cell Surface
por: Lee, Fuiyee, et al.
Publicado: (2014)

Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome
por: Admiraal, Rick, et al.
Publicado: (2019)

Targeting of Natural Killer Cells by Rabbit Antithymocyte Globulin and Campath-1H: Similar Effects Independent of Specificity
por: Stauch, Diana, et al.
Publicado: (2009)

Fludarabine-Melphalan-Campath, Followed by Unmanipulated Peripheral-Blood Haematopoietic Stem Cells, Can Still Cure Lymphoma
por: Avenoso, Daniele, et al.
Publicado: (2023)

Chronic allograft nephropathy
por: Fletcher, Jeffery T., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_0j4rgduk3q9acb6kngjaai3m0f